Dahms Bradford D. 4

What Happened

• Bradford D. Dahms, Chief Financial Officer of Jade Biosciences, was granted two equity awards on 2026-02-12: 37,813 restricted stock units (RSUs) and a derivative award covering 226,875 shares (stock option). Both were reported as acquisitions at $0.00, meaning these are compensation grants (awards), not open-market purchases or sales.

Key Details

• Transaction date: 2026-02-12; Form 4 filed 2026-02-13 (appears timely; Form 4 is typically due within two business days).
• RSU grant: 37,813 RSUs (footnote F1). Vesting: 1/4 of the RSUs vest on each of the first four anniversaries of Feb 15, 2026, subject to continued service. Each RSU represents a contingent right to one share.
• Option/derivative grant: 226,875-share award (footnote F2). Vesting: 25% vests on Feb 15, 2027; remaining 75% vests in equal monthly installments over the next three years, subject to continued service. This award is a right to purchase shares (not an exercised purchase).
• Price and value: $0.00 per share; reported acquisition value $0 (compensation).
• Shares owned after transaction: Not specified in the provided excerpt—see the full Form 4 for total beneficial ownership.

Context

• These entries are equity compensation (awards), which vest over time and do not reflect an immediate cash purchase or sale. The option is not exercised now; it gives the holder the future right to buy shares if and when vested and exercised. Compensation grants are common for executives to align incentives with shareholders and should be viewed differently from open-market buys or sales.